The effect of garlic supplements on the pharmacokinetics of saquinavir

Clinical Infectious Diseases

Volumn 34, Issue 2, 2002, Pages 234-238

  Piscitelli, Stephen C ^a   Burstein, Aaron H ^a   Welden, Nada ^b   Gallicano, Keith D ^c   Falloon, Judith ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c Axelson Biopharma Research Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GARLIPURE; SAQUINAVIR;

ABDOMINAL DISCOMFORT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; GARLIC; HERBAL MEDICINE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; CYTOCHROME P-450 ENZYME SYSTEM; DIETARY SUPPLEMENTS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ENTEROCYTES; FEMALE; GARLIC; HIV INFECTIONS; HIV-1; HUMANS; INTESTINE, SMALL; LONGITUDINAL STUDIES; MALE; PLANT EXTRACTS; SAQUINAVIR;

EID: 0037079915     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/324351     Document Type: Article

References (17)

1. Complementary AIDS therapies: The good, the bad, and the ugly
2. Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients
3. Indinavir concentrations and St John's wort
4. Fat distribution and metabolic changes in patients with HIV infection
5. Hyperlipidemia associated with HIV protease inhibitor use: Pathophysiology, prevalence, risk factors, and treatment
6. Garlic for treating hypercholesterolemia. A meta-analysis of randomized clinical trials
7. 450 3A4 and P-glycoprotein inhibition by galic
8. Alterations in hepatic phase I and phase II biotransformation enzymes by garlic oil in rats
9. 450 3A4: Potential contribution to high first-pass metabolism
10. Pharmaceutical statistics
11. Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection
12. + T-cell counts in HIV-infected patients
13. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients
14. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein
15. Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir
16. A study of pharmacokinetic interactions between garlic supplements and ritonavir in healthy volunteers